By the time I met Kevan Shokat, KRAS G12D was already the name of the devil my body was fighting. Then Kevan did something extraordinary. He made me a three dimensional model of KRAS, had it painted, and sent it to me with a handwritten letter.

more than 60 additional drugs targeting the RAS family are now in development. What began with a chemical foothold in KRAS G12C has become an expanding field of RAS drug discovery. Why This Matters for People With KRAS Cancer The science also explains why knowing the exact KRAS variant matters.

NCCN Guidelines help clinicians determine what evaluations are appropriate, which treatment options are supported by current evidence, when additional testing may be important, and how care may change as a cancer changes.For patients, NCCN offers a version for patients.

KRAS care partner and advocate Chris Conneran joined an international discussion on how artificial intelligence is shaping cancer care, with a focus on patient trust and transparency.

By Terri Conneran, Founder, KRAS Kickers Reviewed for clinical accuracy by Salman R. Punekar, MD, MSc, Perlmutter Cancer Center at NYU Langone Health For this daraxonrasib lung cancer study, eligible RAS mutations were found at G12, G13, or Q61. The exact gene and exact mutation still matter because different RAS mutations can behave differently and may affect treatment or clinical trial options. For example, KRAS G12D, KRAS G12V, and KRAS G12C are all RAS mutations, but they

Expanded Access Can Feel Slow When Treatment Is Urgent. Each EAP has its own criteria for who may receive the drug. If the EAP is for pancreatic cancer, that does not mean it is available for other cancers unless those cancer types are specifically included in the EAP criteria. Every day counts, why does it take so long?

If weight holds steady or rises a little early in treatment, that can be an encouraging sign in lung cancer

Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type. 6 things that matter...

..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.

💡 Why It Matters to Patients: Even if you’re not in the room, what happens at ASCO can shape your treatment options—now and in the future. KRAS-driven cancers (lung, colon, pancreatic, and rare cancers) are a major area of focus at ASCO. knowing what’s coming can help you: -Ask better questions - -Stay ahead of the curve - -Find hope in options you didn’t know existed- Gen-Me Medicine—where cancer care is about matching the right treatment to your unique molecular fingerpri

One of the patient voices from this documentary is Terri Conneran: Empowering the Patients For Precision Cancer Advocacy In the documentary, powerful stories from patients, industry experts, and healthcare providers about how precision medicine has empowered their healthcare decisions, providing renewed hope .

By KRAS Kickers – Cancer Knowledge + Research + Advocacy = Survivorship 📅 May 2025 | 🧬 Published in Blood Cancer Discovery 🔬...

Rare Pancreatic cancer trial comes to you! FGFR + KRAS

Low-Grade Serous Ovarian Cancer (LGSOC) is a rare, slow-growing type of ovarian cancer. It starts in the cells lining the ovaries, fallopian tubes, or peritoneum ...

KRAS Kickers is a cancer patient-led nonprofit organization that shares Knowledge of publicly available Research to empower patients and caregivers to Advocate for Survivorship. Our goal to kick cancer's KRAS!

https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.16_suppl.e23179 Abstract Journal of Clinical Oncology Volume 42, Number 16_suppl June 2024 e23179 Background: Cancer treatments, despite increasing effectiveness, involve significant short and long-term side effects profoundly impacting a person's quality of life (QoL). In response, Advocates for Collaborative Education, a global coalition of patient advocates, initiated an exempt, online survey to gather insights on the percei

Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus. Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference. Biomarkers provide the insights as to what is driving the cancer.

Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...

A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers Brief Summary: "BDTX-4933-101 is a...

" Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with...